ecallantide
Sponsors
Shire, Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Conditions
Blood Loss, SurgicalBloodlossHereditary Angioedema (HAE)Surgical Procedures, Operative
Phase 2
Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement
TerminatedNCT00448864
Start: 2007-05-01End: 2008-08-01Updated: 2019-06-25
A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume
CompletedNCT00816023
Start: 2009-03-31End: 2010-01-31Updated: 2015-08-11
Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery
CompletedNCT00888940
Start: 2009-06-30End: 2010-01-31Updated: 2015-08-10
Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema
WithdrawnNCT01253382
Start: 2012-06-01Updated: 2021-05-18
Phase 3
Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)
CompletedNCT00262080
Start: 2005-12-31End: 2007-02-28Updated: 2021-06-11
Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)
CompletedNCT00457015
Start: 2007-04-01End: 2008-06-01Updated: 2021-06-08
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
CompletedNCT00456508
Start: 2007-04-01End: 2010-09-01Updated: 2021-06-08